Toronto, Ontario – January 30, 2019 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers reports that patient six, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”), has demonstrated no tumour recurrence or presence of disease at the 270 day clinical and cystoscopy assessment. The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and exploratory endpoint of efficacy, primarily at 90 days and secondarily at 180 days post treatment. The Study was successfully completed with patient five and six demonstrating achievement of the primary, secondary and exploratory endpoints. … Read More

Toronto, Ontario – January 9, 2019 Theralase Technologies Inc. (“Theralase®” or “Company”) (TSXV: TLT) (OTCQB: TLTFF) is pleased to announce that it has closed its previously announced non-brokered privateplacement offering (“Offering”) of units (“Units”). On closing, the Corporation issued an aggregate of 4,095,157 Units at a price of $0.35 per Unit for aggregate gross proceeds of approximately $1,433,305. Each Unit consisted of one common share of the Company (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder to acquire an additional Common Shareat an exercise price of $0.50 per share for a period of 24 months following the date of issuance. In connection with the Offering, the Company paid a finder’s fee of $210, and issued 300 finder’s warrants. Each finder’s warrant is exercisable into one Common Share at an exercise price of $0.50 per share for a period of 24 months after the closing … Read More

Toronto, Ontario – December 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”)(TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drugformulations, intended to safely and effectively destroy various cancers, announced today that Health Canada has granted the Company Investigational Testing Authorization (“ITA”) approval to utilize its patent pending TLC-3000 Photo Dynamic Therapy (“PDT”) Laser System, in conjunction with its Clinical Trial Application (“CTA”) approved lead PDC, TLD-1433, to commence enrolling and treating patients in a Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”), subject to submitting a Clinical Trial Site Information Form and receipt of their respective Research Ethics Board (“REB”) approval for each Canadian oncology location that will conduct Study II. The TLC-3000 PDT Laser System delivers green laser light (525 nm), while simultaneously monitoring the laser light to … Read More

Rutherrin® mediated Photo Dynamic Therapy improves cancer specific immune responses by switching the so called “Don’t eat me” signal that cancer cells use to trick the immune system into the “Eat me” signal on treated human glioblastoma cells, a relevant cell model of Glioblastoma Multiforme. Toronto, Ontario – November 30, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers, announced today that Theralase’s Rutherrin® Photo Dynamic Therapy (“PDT”) has been shown to increase its efficacy in cancer treatments, inducing a cancer specific immune response, by switching the so-called “Don’t eat me” signal to an “Eat me” signal on treated human glioblastoma cells. This switch in cellular signalling improves the uptake of treated cancer cells by immune … Read More

Theralase® Granted Canadian Patent for Metal-Glycoprotein Complexes Used to Hunt Cancer Cells and When Laser Light Activated Destroy Them Toronto, Ontario – November 15, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, used to safely and effectively destroy various cancers is pleased to announce that it has been granted a Canadian patent protecting its unique metal-glycoprotein complexes used to hunt cancer cells and when laser light activated destroy them.  The Canadian patent entitled, “Metal-Glycoprotein Complexes And Their Use As Chemotherapeutic Compounds” is critical in protecting Theralase’s systemic and targeted anti-cancer therapies to allow PDCs and their associated drug formulations to be systemically injected to hunt and destroy cancer cells for various cancer conditions.  Arkady Mandel, M.D., Ph.D., D.Sc., Interim Chief Executive Officer and … Read More

Toronto, Ontario – November 29, 2018 “Theralase®” or the “Company” (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy cancer released its 3Q2018 financial statements.  Total revenue for the nine-month period ended September 30, 2018 decreased to $1,276,630 from $1,354,254 for the same period in 2017, a 6% decrease. In Canada, revenue decreased 19% to $847,870 from $1,046,508. In the US, revenue decreased 7% to $253,742 from $272,305 and international revenue increased 393% to $175,018 from $35,441. The increase in international revenue in 2018 and the corresponding decrease in Canadian and US revenue is attributable to the Company hiring an International Sales Manager and restructuring the Canadian and US sales and marketing departments.  Cost of sales for the nine-month period ended September 30, 2018 was $559,296 … Read More

Theralase® Provides Update on 9 months Post Treatment Cystoscopy Analysis Toronto, Ontario – November 8, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers has provided an update on patient five, enrolled and treated in the recently completed Phase Ib Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study”).  The Study’s purpose was to evaluate TLD-1433, Theralase’s lead PDC, for the primary endpoint of safety and tolerability, with a secondary endpoint of pharmacokinetics (movement and exit of drug within tissue) and an exploratory endpoint of efficacy.  Theralase’s Anti-Cancer Treatment involves the instillation of a water-based solution of Theralase’s lead anti-cancer PDC, TLD-1433 at the Therapeutic Dose (0.70 mg/cm2), via a catheter inserted through the urethra into the … Read More

Toronto, Ontario – October 3, 2018 Theralase Technologies Inc. (“Theralase” or “Company”) (TSXV: TLT) (OTCQX: TLTFF) is pleased to announce that it has closed its previously announced non-brokered private placement offering (the “Offering”) of units (“Unit”).  On closing, the Corporation issued an aggregate of 3,157,059 Units at a price of $0.35 per Unit for aggregate gross proceeds of approximately $1,104,970.  Each Unit consists of one common share of the Company (“Common Share”) and one common share purchase warrant (“Warrant”). Each Warrant entitles the holder to acquire an additional Common Share at an exercise price of $0.50 per share for a period of 24 months following the date of issuance. The Company intends to use the proceeds of the Offering for the following: – Advancement of Phase II Non-Muscle Invasive Bladder Cancer clinical study – Working capital and general corporate purposes   The securities offered have not been registered under the … Read More

Theralase® Affiliated Researchers Present New Data that Demonstrates the Application of Theralase’s Lead Photo Dynamic Compound, TLD-1433, in the Destruction of Gastrointestinal Dysplasia and Esophageal Cancer. Toronto, Ontario – October 9, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations intended to safely and effectively destroy various cancers announced today that Theralase affiliated researchers have presented immunohistochemical analytical data supporting the use of TLD-1433 Photo Dynamic Therapy (“PDT”) in the destruction of gastrointestinal dysplasia and esophageal cancer. Esophageal carcinoma, including Squamous Cell Carcinoma (“SCC”) and adenocarcinoma, is a leading cause of cancer related deaths worldwide. While SCC arises through progression from Low Grade Dysplasia (“LGD”) to High Grade Dysplasia (“HGD”), adenocarcinoma is preceded by Barrett’s metaplasia followed by low and then high grade dysplastic changes. There … Read More

Toronto, Ontario – September 10, 2018 Theralase Technologies Inc. (“Theralase®” or the “Company”) (TSXV: TLT) (OTCQX: TLTFF), a clinical stage pharmaceutical company dedicated to the research and development of light activated Photo Dynamic Compounds (“PDCs”) and their associated drug formulations, intended to safely and effectively destroy various cancers, announced today that Health Canada has approved the Company’s Clinical Trial Application (“CTA”), allowing clinical study evaluation of Theralase’s lead anti-cancer drug, TLD-1433. The CTA approval allows Theralase to authorize clinical oncology sites in Canada to enroll and treat patients in a pivotal Phase II Non-Muscle Invasive Bladder Cancer (“NMIBC”) clinical study (“Study II”), pending Health Canada Investigational Testing Authorization (“ITA”) for the Theralase TLC-3200 Medical Laser System and Research Ethics Board (“REB”) approval, both expected in due course. Study II titled, “A Phase II Clinical Study of Intravesical Photo Dynamic Therapy in Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer or Patients … Read More